canagliflozin

This page shows the latest canagliflozin news and features for those working in and with pharma, biotech and healthcare.

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin).

J&J’s Invokana gets lifeline with new kidney disease approval

Based on the results of the CREDENCE trial, Invokana (canagliflozin) has become the only drug in the SGLT2 inhibitor class to be approved for treating diabetic kidney disease (DKD), and to
AZ claims first-in-class win for Farxiga in heart failure

At the same time, first-to-market SGLT2 inhibitor Invokana (canagliflozin) from Johnson &Johnson has been shrinking since the FDA added a label warning of lower-limb amputations risk in 2017.
Boehringer posts solid first half as business revamp beds in

failure risks in diabetes patients, as well as side-effect concerns that have dogged Johnson &Johnson’s first-to-market rival Invokana (canagliflozin).
AZ says Farxiga cuts kidney disease in type 2 diabetes

At the same time first-to-market Invokana (canagliflozin) from Johnson &Johnson – which also has positive results on renal disease from the CREDENCE study – has been shrinking since the FDA added
Pfizer closes on EU approval of lung cancer drug Vizimpro

The drug is also under regulatory review for this indication in the US and Japan, and the new use could help AZ compete in the market with SGLT2 rivals Invokana (canagliflozin)

More from news
Approximately 8 fully matching, plus 52 partially matching documents found.

Market dynamics, marketing and analytics

Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.
Interview: Christopher Boulton, AstraZeneca

Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and
Pharma deals during April 2013

Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor—Invokana (canagliflozin).
Interview: Cesar Rodriguez, Janssen

In addition, the company is planning its move into endocrinology, with the launch of its first diabetes medicine canagliflozin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Associate Director - Global Healthcare Consulting: £100,000 - £115,000 yearly

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Add my company

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...

Email:
Password: